Background: Intracranial hemorrhage (ICH) is the second leading cause of mortality in patients with acute myeloid leukemia (AML). However, the prognostic factors for ICH in AML patients are still under investigation.
introduction
Intracranial hemorrhage (ICH) is a catastrophic hemorrhagic complication in patients with hematological malignancy [1] [2] [3] . ICH in patients with hematological malignancy may have several risk factors, including hypertension, vessel wall abnormalities, low platelet count, platelet dysfunction, coagulation factor deficiency, disseminated intravascular coagulation (DIC), sepsis, and hyperleukocytosis [1, [4] [5] [6] . Acute promyelocytic leukemia (APL) is the notorious subtype which causes fatal ICH in the acute myeloid leukemia (AML) patients. Clinically significant coagulopathy is present in 70%-80% of APL patients upon disease diagnosis [7, 8] ; 14% of patients die of fatal hemorrhage during induction therapy [8] [9] [10] . Under all-trans retinoic acid (ATRA) treatment, APL has been well controlled and the early mortality is significantly decreased [11, 12] . Prophylactic platelet transfusions which maintain the safety threshold in patients with hematological malignancy also lower the hemorrhagic complications [13] [14] [15] [16] . Though supportive treatments have been much improved during the past several years, cerebral hemorrhagic complications are still not uncommon in patients with AML [17] [18] [19] [20] . Though treatment and outcome have demonstrated remarkable progress for ICH in the general population, mortality is still extremely high in patients with hematological malignancy. Most patients who develop ICH die within 24-48 h, but some patients survive [4, 17, 19] . ICH can be classified into intraparenchymal hemorrhage (IPH), subarachnoid hemorrhage (SAH), subdural hemorrhage (SDH), and epidural hemorrhage (EDH) [4] . Different locations and types of ICH may influence outcomes; however, clinical experiences concerning ICH with hematological malignancy are limited in the literature. The prognostic factors in AML patients after ICH are still under investigation. We reviewed the data for all AML patients with ICH admitted from 1995 to 2007 to the National Taiwan University Hospital. The clinical characteristics, image study, and prognostic factors for ICH were analyzed.
patients and methods
patients National Taiwan University Hospital is a 2200-bed teaching hospital in Central Taipei that provides both primary and tertiary care. Eight hundred and forty-one adult patients (480 men), diagnosed as having AML, were admitted to the Department of Internal Medicine from January 1995 to December 2007 and were enrolled in this study. The median age was 52 (range . The laboratory data were collected at near or just onset of ICH. Demographics, hematological disease status, underlying medical diseases, laboratory data, clinical and imaging findings of ICH, and outcomes were reviewed and analyzed retrospectively. 
diagnosis of ICH
ICH diagnosis was determined from both clinical and imaging findings. Either computed tomogram or magnetic resonance imaging was required to confirm the clinical diagnosis of ICH. Those that were suspected of but unproven for ICH were excluded. Types and locations of brain hemorrhage were determined according to the radiology reports. According to imaging, hemorrhage types were classified into IPH, SAH, SDH, and EDH [4] . Early ICH was defined as ICH within 7 days of acute leukemia diagnosis, including as an initial presentation. ICH that occurred 7 days after diagnosis was deemed late ICH [18] .
end points and overall survival
The starting point was the date of diagnosis of ICH. The primary end point was ICH-related death within 30 days. Survival time was the time interval from diagnosis of ICH to events such as death from any cause.
statistical analysis
For continuous variables, data are given as medians (range). For nominal variables, data are reported as the number of patients, unless specified otherwise. Survival curves were plotted using Kaplan-Meier; differences between curves were analyzed by log rank. All factors in univariate analyses were enrolled in the multivariate analysis using Cox proportional hazard testing. All statistical analysis was carried out using SPSS 13.0 for Windows (SPSS, Chicago, IL); P < 0.05 were considered statistically significant.
results

ICH in AML patients
Among the 841 patients with AML, 51 (37 men) developed ICH; 18 had early ICH and 33 were late. The median age was 51 (range 17-86). Twelve of 65 (18.4%) APL patients and 39 of 776 (5%) non-APL patients developed ICH. Patients with APL had significantly higher risks for ICH than those patients with other subtypes of AML (P = 0.001). There were no differences in gender and age between the patients with and without ICH. Most ICH patients (43 of 51, 84%) were in refractory/relapse for leukemia. Only eight patients were in remission. Seven of 18 patients with early ICH and one with late ICH had white blood cell (WBC) counts >100 000/ll at diagnosis (39% versus 3%, P = 0.002). Ten of 18 patients had prolonged prothrombin time (PT) international normalized ratio (INR) >1.5 developed early ICH (P = 0.035). Hyperleukocytosis and prolonged PT are risk factors for early ICH in AML patients.
correlation of clinical features and ICH
The clinical characteristics and outcomes of ICH in AML patients are shown in Table 1 . Only one of the 18 patients with prolonged PT (INR > 1.5) survived while the other 17 died of ICH. Patients with prolongation of PT had significantly higher risks of 30-day death in univariate analysis (P < 0.001). Univariate analysis also revealed that those over 60 had better prognoses than younger patients (P = 0.035). This result may stem from the fact that the elderly patients had high percentages of SDH while younger patients had more SAH as shown in the Table 2 . Underlying hypertension, sepsis, preceding myelodysplastic syndrome, and hematopoietic stemcell transplantation did not influence the 30-day outcomes after ICH in AML patients.
correlation of location and type of hemorrhage and ICH
Correlations of clinical characteristics with types of ICH are shown in Table 2 . IPH is associated with male gender (P = 0.027) and prolonged PT (P = 0.017). SAH is associated with absence of prior hypertension (P = 0.043), less advanced age (£60 years) (P = 0.064), and sepsis (P = 0.054). SDH is associated with advanced age (P = 0.008) and negatively associated with prolonged PT. Eight patients who had received prior hematopoietic stem cell transplantation developed IPH (five cases) and SAH (three cases). ICH type showed no significant differences in terms of reception of hematopoietic stem-cell transplantation. Patients with APL often presented catastrophic hemorrhage; 6 of 12 had hemorrhage rupture into the ventricles (P = 0.05). No APL patients presented SDH.
ICH occurred in the supratentorium (44 cases), basal ganglion (nine cases), cerebellum (five cases), and brain stem (four cases) ( Table 3) . Twenty-one patients (37%) had multiple sites, indicated by imaging. Thirty-eight patients had IPH (including 12 with both IPH and SAH, two with both IPH and SDH), 16 patients had SAH, 10 had SDH, and one had EDH. Hemorrhage ruptured into the ventricles in 13 patients.
outcome and prognostic factors after ICH in AML patients
Most patients received supportive treatment after ICH developed because of bleeding tendencies and underlying leukemic status. Only four patients received surgical intervention for ICH. Three patients with underlying AML (non-APL) underwent craniotomy and hematoma evacuation, all of whom survived. One APL patient with SAH with ventricular rupture received external ventricular drainage and died 6 days later. Nineteen patients (37%) died within 3 days of ICH; 34 (67%) died within 30 days. SAH patients had an extremely high mortality rate (94%), but patients with SDH only had a 27% rate. All covariates of ICH were enrolled in the multivariate analysis. Multivariate analysis was carried out using the Cox proportional hazard test. Poor outcomes of ICH in AML patients were associated with four independent factors, prolonged PT (P < 0.001), brainstem hemorrhage (P = 0.001), SAH (P = 0.017), and EDH (P = 0.014) ( Table 4) .
discussion
Recent improvements in surgical and critical care, the morbidity, and mortality rates for ICH in the general population have improved [21, 22] . There has been remarkable progress in supportive care of AML during the past decade. ATRA significantly reduces the early bleeding complications of APL [11, 23] . Since APL patients received different induction therapies before the ATRA era, the incidence of ICH is unknown in the post-ATRA era. Kim et al. reported a 5.3% incidence of ICH in patients with acute leukemia from 1989 to 2003 [17, 18] . In this AML cohort, 51 of 841 (6%) patients were diagnosed with ICH. This is a relatively large cohort study of ICH in AML patients in the post-ATRA era. However, all APL patients received ATRA as induction regimens in this study eventually; the APL patients still had a relatively higher rate of ICH compared with those patients with other subtypes of AML (P = 0.001). Hyperleukocytosis (WBC count over 100 000/ll) has been recognized as a risk factor for ICH in patients with AML [24, 25] . In this study, hyperleukocytosis is significantly associated with early ICH but not with late ICH. Early and intensive treatment of hyperleukocytosis may reduce the risk of ICH. Prolonged PT was found to be a risk factor of spontaneous ICH in a previous study [26] . In this study, AML patients with prolonged PT had a significantly poorer prognosis after ICH (P < 0.001). Hypertension is the major risk factor for ICH and increases the risk about fourfold in the general population [22] . Up to half of hypertensive patients who suffer from ICH are unaware of their hypertension, noncompliant with medication, or fail to control periodically their blood pressure levels. However, underlying hypertension did not increase the risk of ICH in AML patients in this study. Since all patients developed SAH without prior hypertension history, ICH could not be excluded in AML patients who developed neurological abnormalities without preceding hypertension history. Sepsis and DIC are risk factors for ICH in patients with hematological malignancy [1] [2] [3] 26] . Kawanamii et al. [27] reported that 5 of 14 autopsied acute leukemic patients had invasive fungal cerebral infection. These findings may explain how some ICH may be caused by sepsis, especially in invasive fungal infection. Nevertheless, there were no autopsies in our series and further studies are needed to clarify the relationship between invasive fungal infection and ICH.
Imaging concerning types and locations of ICH in patients with AML are limited in the current literature. Yamauchi et al. [4] reported that 37% of his patients were diagnosed with IPH, 34% had both IPH and SAH, and 16% had SAH among 38 patients with AML. Subdural hematoma occurred only in 6% of AML patients. Bleggi-Torres et al. [19] reported that 12 of 16 (75%) cases had IPH and SAH as the main causes of death in an autopsy study of 58 bone marrow transplants. IPH and SAH events occurred in 75%-87% of AML patients and these findings were consistent with our cohort. In our study, 47% of patients were diagnosed with IPH, while 24% had both IPH and SAH, and 8% had SAH. SDH is relatively less common in patients with AML.
Thirty-four of 51 (67%) AML patients died of ICH (30 days) in this study. The patients with SAH had high mortality (94%) while the patients with SDH were relatively low (27%). This result confirms that different types of brain hemorrhage may disclose different outcomes in AML patients. Patients with SDH have relatively favorable outcome as cancer patients [28, 29] . Ten patients (20%) were diagnosed with SDH and eight of them were over 60. The prognostic effect of age may be confounded by ICH type (Table 2) .
Maybe poor outcome of ICH in cancer patients, rare studies concern the prognostic factors for AML patients with ICH. Kim et al. proposed a risk score model for intracranial hemorrhaging in acute leukemia [17, 18] . Gender (female), leukocytosis, APL, thrombocytopenia, and PT are significantly associated with fatal ICH. Image study is a powerful tool in diagnosis and prognosis prediction of ICH in cancer patients. Imaging results and the overall outcomes may differ with types and locations of ICH. In the current study, multivariate analysis revealed four independent prognostic factors, prolonged PT (P < 0.001), brainstem hemorrhaging (P = 0.001), SAH (P = 0.017), and EDH (P = 0.014). Gender, APL, leukocyte count, and platelet count were not independent prognostic factors in ICH patients with AML. Types and locations of ICH play an important role in the prognosis of AML patients.
Most patients with underlying hematological malignancy could not undergo surgical intervention during the nadir stage, postchemotherapy. Recently, activated factor VII has been successfully used for some cases of myeloid leukemia [30] [31] [32] . However, thrombotic events such as myocardial infarction and ischemic strokes also developed in some patients in some studies [33, 34] . Large-scale studies of patients with hematological malignancy are needed.
ICH leads to high morbidity and mortality in the patients with AML. Early detection of coagulopathy and prompt correction can reduce hemorrhagic complications. Locations and types of ICH can predict outcomes; an emergent image study is recommended in suspicious of ICH in cancer patients. Novel treatment of coagulopathy should be investigated for groups with poor prognosis in terms of AML with ICH. 
references
